Because the systemic bioavailability is <1% (using a sensitive assay with a lower quantitation limit of 0.25 pg/ml) after administration of mometasone furoate via Mometasone furoate (NASONEX) Aqueous Nasal Spray, overdose is unlikely to require any therapy other than observation.